 |
|
 |
 |
| MarketVIEW: Rotavirus vaccines |
 |
 |
 |
Published June 2014
Rotavirus transmitted by the faecal oral route causes fever and vomiting followed by diarrhoea/dehydration in neonates and infants.
Recovery is usually complete but in the developing world, the virus is responsible for 5% of all deaths among children below five yrs
(453,000 deaths in 2008).
Improvements in water quality and sanitation do not adequately prevent the spread of rotavirus such that vaccination is the best way
to prevent severe infection. In 2009, the WHO recommended that rotavirus vaccines be included in all national immunisation
programs and considered a priority. Two rotavirus vaccines, Rotarix (GSK Biologicals) and Rotateq (Merck & Co) have been licensed
since 2006 and are used in both Western and developing world countries. New rotavirus vaccines are in development which may
address the limitations of Rotarix and Rotateq.
This MarketVIEW comprehensive commercial opportunity assessment detailing the current and potential market for
Rotavirus vaccine(s) using a patient based value/volume forecast for major Western markets, BRIC-MIT and GAVI countries to 2030.
The forecast gives revenues and volume shares per vaccine per region taken into account the launch of new products and roll out
into GAVI countries. The analysis also provides an update on competitor R&D activity and includes a detailed update of country
national immunisation program parameters to date.
THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20% (from January 2011)
Please review the TERMS and CONDITIONS of purchase.
|
 |
|
 |
|
|